Evidence map›Paper›PMID 39270036›Full record

ReviewCancer immunology research2024

The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer.

Sreya Ghosh, Ivan Zanoni

Abstract readReview
In one paragraph

Review in Cancer immunology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Neutrophil and Colorectal Cancer.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sreya GhoshHarvard Medical School, and Division of Immunology, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0003-2956-4830
Ivan ZanoniHarvard Medical School, and Division of Immunology, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0002-3423-7474

Funding

Type III interferon Control of Mucosal ImmunityR01DK115217 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Scott B Snapper, Ivan Zanoni · 2017 to 2026
$5.6M
COOPERATIVE MINORITY BIOMEDICAL PROGRAM-CCSG-AFFILICATEU10CA003888 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI DINNDORF, PATRICIA A · 1985 to 2002
$998k
Cancer Research Institute (CRI) Lloyd J. Old STAR Program CRI3888Crohn's and Colitis Foundation (CCF) Award #1166137NIDDK NIH HHS R01 DK115217NIH-NIDDK R01DK115217Wellcome Trust
6 · The paper itself

Abstract

Neutrophils are the primary myeloid cells that are recruited to inflamed tissues, and they are key players during colitis, being also present within the tumor microenvironment during the initiation and growth of colon cancer. Neutrophils fundamentally serve to protect the host against microorganism invasion, but during cancer development, they can become protumoral and lead to tumor initiation, growth, and eventually, metastasis-hence, playing a dichotomic role for the host. Protumoral neutrophils in cancer patients can be immunosuppressive and serve as markers for disease progression but their characteristics are not fully defined. In this review, we explore the current knowledge on how neutrophils in the gut fluctuate between an inflammatory or immunosuppressive state and how they contribute to tumor development. We describe neutrophils' antitumoral and protumoral effects during inflammatory bowel diseases and highlight their capacity to provoke the advent of inflammation-driven colorectal cancer. We present the functional ambivalence of the neutrophil populations within the colon tumor microenvironment, which can be potentially exploited to establish therapies that will prevent, or even reverse, inflammation-dependent colon cancer incidence in high-risk patients.

Indexed as

Colitis-Associated NeoplasmsNeutrophilsTumor MicroenvironmentAnimalsColitisHumans

Identifiers

PMID39270036
PMCPMC11444878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.